Dihydroergocornine
Dihydroergocornine Uses, Dosage, Side Effects, Food Interaction and all others data.
Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects. It is an artificial derivative of the crude extract of ergot and later purified, ergocornine. The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid. Dihydroergocornine presents a formula of 9,10 alpha-dihydro-12'-hydroxy-2',5'alpha-bis(1-methylethyl)-ergotaman-3',6',18-trione. It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to Ergoloid mesylate
It is reported that dihydroergocornine administration, in non-toxic doses, presents sympatholytic and hypotensive properties which are observed as a significantly decreased mean arterial pressure. In the brain, the activity of dihydroergocornine was observed as a decrease in cerebral blood flow, cerebral vascular resistance and oxygen uptake. The effect in the brain seems to allow a cerebral metabolic homeostasis. To know more about the pharmacology please visit Ergoloid mesylate
| Trade Name | Dihydroergocornine |
| Generic | Dihydroergocornine |
| Dihydroergocornine Other Names | Dihydroergocornine |
| Type | |
| Formula | C31H41N5O5 |
| Weight | Average: 563.699 Monoisotopic: 563.31076944 |
| Protein binding | To know more about the pharmacokinetics please visit Ergoloid mesylate. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Dihydroergocornine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.
To know more about the approved indications please visit Ergoloid mesylate
Dihydroergocornine is also used to associated treatment for these conditions: No primary neurologial disease, idiopathic decreased mental activity
How Dihydroergocornine works
The mechanism of action by which dihydroergocornine exerts its effects are not entirely defined. However, it is reported that dihydroergocornine has central and peripheral effects. The fall in blood pressure seems to be related to the stimulation of the vasodilator center. It has been demonstrated that dihydroergocornine possesses potent adrenolytic and sympathicolytic actions. The effect of dihydroergocornine is related to the inhibitory effect against the serotonin and noradrenaline receptors in which dihydroergocornine seems to be very potent against a stimulation-induced noradrenaline overflow. It also presents a stimulatory effect in arterial and venous smooth muscle when administered at slightly higher concentrations than the necessary for the inhibitory effect.
Toxicity
Dihydroergocornine effect on fertility was tested in preclinical studies. The reported effect was a decreased weight gain in neonates. Overdosing has also been reported to present effects of fall of blood pressure and a decrease in heart rate to 13 beats per minute. To know more about the pharmacokinetics please visit Ergoloid mesylate.
Food Interaction
No interactions found.Volume of Distribution
To know more about the pharmacokinetics please visit Ergoloid mesylate.
Elimination Route
Dihydroergocornine absorption in man after oral administration is very rapid when compared to the mixture or most of the components. The time to reach maximum plasma concentration or 0.57 ng-eq/ml is 1.4 hours. It presents an absorption half-life of 0.32 hours. The absorption percentage is of about 25% which corresponds to the registered absorption presented in the ergoloid mixture. To know more about the pharmacokinetics please visit Ergoloid mesylate.
Half Life
To know more about the pharmacokinetics please visit Ergoloid mesylate.
Clearance
No pharmacokinetic related to the clearance rate was found in current literature.
Elimination Route
When orally administered, dihydroergocornine is almost completely eliminated via feces. The urinary secretion accounts only for 2.5% of the administered dose. On the other hand, when administered intravenously, the renal excretion can account for approximately 10% of the administered dose. To know more about the pharmacokinetics please visit Ergoloid mesylate.
Innovators Monograph
You find simplified version here Dihydroergocornine
